Abstract
On October 15, 2014, a workshop was held on the use of clinical outcome assessments in clinical trials for high-grade glioma of the brain. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, the Musella Foundation for Brain Tumor Research and Information, and Accelerate Brain Cancer Cure. It was planned and carried out with participation from the US Food and Drug Administration. The workshop also included stakeholders from all aspects of the brain tumor community, including clinicians, researchers, industry, clinical research organizations, patients and patient advocates, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to move the field forward and toward greater inclusion of these endpoints in future clinical trials for high-grade gliomas.
Original language | English (US) |
---|---|
Pages (from-to) | ii26-ii36 |
Journal | Neuro-oncology |
Volume | 18 |
DOIs | |
State | Published - Mar 1 2016 |
Keywords
- brain tumor
- clinical outcome assessment
- endpoints
- high-grade gliomas
- patient-reported outcomes
ASJC Scopus subject areas
- Oncology
- Clinical Neurology
- Cancer Research